On August 9, 2023, Syros Pharmaceuticals, Inc. received notice from Incyte Corporation that Incyte has elected to terminate the Target Discovery, Research Collaboration and Option Agreement dated January 8, 2018 by and between the Company and Incyte (the Agreement") related to the discovery, development and commercialization of novel therapies for myeloproliferative neoplasms. Incyte exercised its right to terminate the Agreement for convenience. The termination will be effective within sixty days of August 9, 2023. Under the terms of the Agreement, the Company agreed to identify and conduct initial validation of novel therapeutic targets with a focus on myeloproliferative Neoplasms, and Incyte received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for the development and commercialization of therapeutic products directed to up to seven validated targets.

The Company completed all of its allocated target identification and validation activities under the Agreement. Incyte elected not to exercise its option rights to any of the identified targets. Incyte previously paid the Company $10.0 million in up-front consideration in connection with entering into the Agreement.

The Company was also eligible to receive certain target selection milestone payments and option exercise fees if Incyte selected targets for validation and exercised its options to obtain exclusive rights to collaboration intellectual property for therapeutic products directed to validated targets, as well as other potential development, regulatory and commercial milestone payments and low single-digit royalties on net sales for any therapeutic product resulting from the collaboration. The Company will not receive any of these milestone payments or royalties.